Evolving Strategies for the Management of Obstructive Hypertrophic Cardiomyopathy

Area of Science:

• Cardiology
• Pharmacology
• Genetics

Background:

• Hypertrophic cardiomyopathy (HCM) treatment historically relied on non-disease-specific therapies.
• HCM is characterized by abnormal actin-myosin interactions leading to hypercontractility.

Purpose of the Study:

• To evaluate the efficacy and safety of cardiac myosin modulators in treating obstructive HCM.
• To assess the impact of mavacamten on exercise capacity, left ventricular outflow tract obstruction, and symptoms.

Main Methods:

• Review of recently published randomized clinical trials on cardiac myosin modulators.
• Analysis of data on mavacamten's effects on patient outcomes and potential need for septal-reduction therapy.

Main Results:

• Mavacamten demonstrated significant improvements in exercise capacity, left ventricular outflow tract obstruction, and symptoms in obstructive HCM patients.
• Mavacamten may potentially delay the requirement for septal-reduction therapy.

Conclusions:

• Cardiac myosin modulators represent a novel therapeutic approach for obstructive HCM by targeting the underlying pathophysiology.
• Long-term real-world data are necessary to fully establish the safety and efficacy of mavacamten.
• Careful patient selection and shared decision-making are crucial due to HCM's heterogeneity and potential for varied responses to mavacamten.